REGN

Regeneron Pharmaceuticals, Inc.

1,028.87 USD
+18.29 (+1.81%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Regeneron Pharmaceuticals, Inc. stock is up 4.49% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 41.18% of the previous 33 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 5 PUTs, 5 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
12 Jun 14:28 16 Jan, 2026 980.00 PUT 20 25
12 Jun 16:22 20 Jun, 2025 1,200.00 CALL 50 84
12 Jun 17:17 17 Jan, 2025 1,120.00 CALL 30 116
12 Jun 17:37 17 Jan, 2025 980.00 PUT 20 49
12 Jun 17:38 16 Jan, 2026 980.00 PUT 20 25
12 Jun 17:40 15 Nov, 2024 980.00 PUT 10 1
12 Jun 17:41 17 Jan, 2025 980.00 PUT 10 49
12 Jun 19:01 16 Aug, 2024 1,000.00 CALL 15 63
12 Jun 19:32 14 Jun, 2024 970.00 CALL 5 8
12 Jun 19:42 16 Aug, 2024 985.00 CALL 47 49

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema. Dupixent injection is used to treat atopic dermatitis and asthma in adults and pediatrics. Kevzara solution for treating rheumatoid arthritis in adults.

  • RBC Capital
    Tue Jun 4, 09:50
    buy
    confirm
  • Evercore Partners
    Tue May 14, 05:12
    buy
    initial